Ethel Weld, HIVR4P 2021: Long-acting Cabotegravir in HIV Prophylaxis (Part 2)

We had the pleasure of meeting with Ethel Weld (Johns Hopkins University School of Medicine, Baltimore, MD, US) to discuss long acting cabotegravir in HIV prophylaxis.

Part 1 of the discussion can be viewed here.

The abstract entitled: ‘Distribution of long-acting (LA) cabotegravir (CAB) in plasma, mucosal tissues, and associated fluids after a single ultrasound-guided intramuscular (IM) injection in healthy adult participants’ (OA04.03) was presented at the HIVR4P Virtual Conference 2021, 27 January 2021.

Questions:

1. Could you give us an overview of the study and its findings? (0:19)
2. Why was it important to evaluate CAB LA levels in plasma, mucosal tissue and associated fluids? (1:29)
3. How can the distribution of CAB help inform future studies? (6:18)

Disclosures: Ethel Weld has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed in coverage of the HIVR4P 2021 Virtual Meeting.